Cambridge Investment Research Advisors
XLRN

Cambridge Investment Research Advisors’s Acceleron Pharma XLRN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,974
Closed -$373K – 3256
2021
Q2 		$373K Buy
2,974
+54
+2% +$6.81K ﹤0.01% 2294
2021
Q1 		$396K Buy
2,920
+200
+7% +$25.8K ﹤0.01% 2071
2020
Q4 		$348K Sell
2,720
-1,018
-27% -$119K ﹤0.01% 2029
2020
Q3 		$421K Buy
+3,738
New +$372K ﹤0.01% 1717

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cambridge Investment Research Advisors's XLRN Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 2,974 shares — an estimated $373K sold.

Cambridge Investment Research Advisors first reported a position in XLRN in Q3 2020 and held it in 4 quarters. The position peaked at $421K in Q3 2020. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,974 Acceleron Pharma shares in Q3 2021, an estimated $373K.
  • Cambridge Investment Research Advisors first reported a position in Acceleron Pharma in Q3 2020 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Acceleron Pharma position peaked at $421K in Q3 2020.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.